Business
Cryoport Further Expands its Asia Pacific Operations with New Global Logistics Center in Singapore
CRYOPDP named Best Clinical Trial Logistics Provider at the Asia Pacific Bioprocessing Excellence Awards 2021 NASHVILLE, Tenn., May 19, 2021 /PRNewswire/ --
About this update from Cryoport, Inc.
[{"type":"text","content":"CRYOPDP named Best Clinical Trial Logistics Provider at the Asia Pacific Bioprocessing Excellence Awards 2021\n\n\nNASHVILLE, Tenn., May 19, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (\"Cryoport\" or the \"Company\"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that its wholly owned operating companies, Cryoport Systems and CRYOPDP, have jointly opened a new Global Logistics Center in Singapore.\n\n \n \n \n \n \n \n\n \nThe Singapore location is another step in Cryoport's strategy to strengthen its footprint in the Asia Pacific (APAC) region to meet the increasing demand by the life sciences industry for its temperature-controlled supply chain solutions. This follows the launch of Cryoport Systems' and CRYOPDP's first jointly operated Global Logistics Center in Osaka, Japan in the fourth quarter of 2020. As with all the Company's existing Global Logistics Centers, the Singapore facility is outfitted to handle all Cryoport solutions, with capabilities covering the full temperature range from -196° Celsius and every single gradient, up to and including Controlled Room Temperature (CRT). \nAs of March 31, 2021, Cryoport supported 543 clinical trials in regenerative medicine globally, with 28 of those clinical trials being in the APAC region. An important example of growing demand in Singapore is driven by our partner, Lonza, which has a key clinical and commercial cell therapy facility on the island nation. In addition, a number of therapies supported by Cryoport have recently been approved in the APAC region, some examples are Novartis' commercial therapy KYMRIAH®, which is approved in Japan, Singapore and Australia and Bristol Myers Squibb's commercial therapy BREYANZI®, which was approved in Japan. These commercial therapies represent part of the first wave of expected commercial approvals in the APAC region and Cryoport is continuing to build out our position to support the growing number of commercial therapies in this region. This includes leveraging CRYOPDP's leading position in key APAC countries such as Singapore, Japan, South Korea and Australia, and its many years of experience providing premium and white glove services to thousands of life sciences clients in the region, to provide its clients with seamless and comprehensive solutions. \nJerr...